← Back to Search

Other

Curcumin for Tinnitus

N/A
Waitlist Available
Led By Seilish Babu, MD
Research Sponsored by Ascension South East Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults with subjective tinnitus due to sensorineural hearing loss as determined by routine audiogram.
Be older than 18 years old
Must not have
Adults with subjective tinnitus due to another cause
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluate at the beginning of the trial and at the end of the 30 day treatment period.
Awards & highlights

Summary

This trial will study whether highly bioavailable curcumin can help to reduce tinnitus symptoms.

Who is the study for?
This trial is for adults who have ringing in their ears (tinnitus) because of hearing loss from nerve damage. They must not be allergic to the test compounds, pregnant, using other tinnitus treatments like certain medications or counseling, or taking blood thinners.Check my eligibility
What is being tested?
The study is testing if a form of curcumin that's easy for the body to use can help with tinnitus. Participants will either get this special curcumin or a placebo and answer surveys about their tinnitus before and after treatment.See study design
What are the potential side effects?
Curcumin might cause digestive upset, headaches, rashes, or yellow stool. It could also interact with other drugs. However, since it's generally considered safe at low doses, serious side effects are rare.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have tinnitus due to hearing loss, confirmed by a hearing test.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have tinnitus not caused by hearing loss.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluate at the beginning of the trial and at the end of the 30 day treatment period.
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluate at the beginning of the trial and at the end of the 30 day treatment period. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change on the Tinnitus Functional Index (TFI)
Secondary outcome measures
Determine Changes in the Tinnitus Handicap Inventory (THI)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment GroupExperimental Treatment1 Intervention
Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for tinnitus often include anti-inflammatory and antioxidant agents, such as highly bioavailable curcumin. These treatments work by reducing inflammation and oxidative stress in the auditory pathways, which are believed to contribute to tinnitus. By mitigating these underlying factors, these treatments can potentially decrease the severity of tinnitus symptoms. This is crucial for patients as it can improve their quality of life by reducing the constant ringing or buzzing in their ears, which can be debilitating and affect daily activities.

Find a Location

Who is running the clinical trial?

Ascension South East MichiganLead Sponsor
18 Previous Clinical Trials
32,313 Total Patients Enrolled
Seilish Babu, MDPrincipal InvestigatorMichigan Ear Institute
1 Previous Clinical Trials
6 Total Patients Enrolled

Media Library

Highly Bioavailable Curcumin (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04800107 — N/A
Tinnitus Research Study Groups: Treatment Group, Placebo Group
Tinnitus Clinical Trial 2023: Highly Bioavailable Curcumin Highlights & Side Effects. Trial Name: NCT04800107 — N/A
Highly Bioavailable Curcumin (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04800107 — N/A
Tinnitus Patient Testimony for trial: Trial Name: NCT04800107 — N/A
~32 spots leftby Dec 2025